Positionspapier zu Psychedelika assistierter Therapie von Abhängigkeitserkrankungen der Schweizerischen Gesellschaft für Suchttherapie
SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice December 1, 2025 Alexander Wopfner, Thilo Beck, Louise Penzenstadler
The Swiss Society for Addiction Medicine (SSAM) advocates for evidence-based, patient-oriented treatment of addiction disorders. Given recent scientific findings and international developments, SSAM evaluates psychedelic-assisted psychotherapy (PAT) with classic psychedelics such as LSD or psilocybin and the atypical psychedelic ketamine as a therapy option for addiction disorders when guideline-based treatments do not provide sufficient stability. SSAM also supports an open, evidence-based debate on the legalization and appropriate regulation of classic and atypical psychedelics, including LSD, psilocybin, and the most widely used non-medical entactogen MDMA, in Switzerland. This includes both therapeutic applications and use outside a medical context to promote harm reduction and enable access to safe, quality-controlled substances.